Eupraxia Pharmaceuticals News - August 2026
🟢 Eupraxia Pharmaceuticals is trading 13% up in pre-market after Q2 report highlighted $133.7 million liquidity
Eupraxia Pharmaceuticals is trading sharply higher at $7.30, up +12.65%, after its August 11 Q2 report highlighted $133.7 million in liquidity and cash runway...
🟢 Eupraxia Pharmaceuticals is trading 8% up today in pre-market after Q2 EPS beat
Eupraxia Pharmaceuticals is trading $7.00 (+8.02%) in pre-market after reporting Q2 EPS of $(0.23), beating the $(0.25) estimate. - Management reported $133.7...
Eupraxia Pharmaceuticals' second quarter 2026 EPS beat estimates as liquidity reached $133.7M
Eupraxia Pharmaceuticals reported a net loss of $14.5 million for the second quarter of 2026, outperforming analyst expectations for the period. As a...
Eupraxia Pharmaceuticals Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
For the second quarter of 2026, analysts expect Eupraxia Pharmaceuticals to report a consensus loss per share of $0.25 on zero revenue, with the current stock...
🟢 Eupraxia Pharmaceuticals is trading 12.6% up in after-hours trading — move remains unexplained
Eupraxia Pharmaceuticals is trading at $7.50 (+12.61%) in after-hours trading; the move remains unexplained. - No confirmed August 6, 2026 company-specific...